The 7 most recent market catalysts affecting $APMD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
Apimeds Pharmaceuticals shares are trading higher after the company announced its subsidiary, MindWave, signed a 12-month technology services agreement with AQUAE Holdings to deploy its MindChain infrastructure as the foundation of AQUAEChain.
This headline represents a significant corporate catalyst for Apimeds Pharmaceuticals. The agreement for MindWave's MindChain infrastructure to be deployed by AQUAE Holdings sugges…
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 55
Apimeds Pharmaceuticals Enters First Amendment To Settlement Agreement On Sept. 10; Board To Consist Solely Of Four Members During Interim Period; Board To Expand To Seven Members After Interim Period; Amends Settlement Agreement With Inscobee Parties
Apimeds Pharmaceuticals (APMD) has entered into a First Amendment to a Settlement Agreement with the Inscobee Parties. This amendment primarily concerns the composition of its Boar…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 95
Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M
Apnimed (APMD) announced Q2 earnings of $3.91 per share, dramatically exceeding the analyst consensus estimate of $(0.34) by 1250 percent. This substantial beat, alongside $12.080 …
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 65
LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50
LifeSci Capital's initiation of coverage on Apnimed with an 'Outperform' rating and a $50 price target is a positive development for the company. This signals that a reputable fina…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 65
Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60
Cantor Fitzgerald analyst Josh Schimmer has initiated coverage on Apnimed (APMD) with an 'Overweight' rating and a $60 price target. This event is significant as new analyst covera…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 65
Evercore ISI Group Initiates Coverage On Apnimed with Outperform Rating
Evercore ISI Group, a prominent investment bank, has initiated coverage on Apnimed with an 'Outperform' rating. This event is significant because analyst coverage, especially from …
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 65
B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41
B of A Securities analyst Jason Gerberry has initiated coverage on Apnimed (APMD) with a 'Buy' rating and a $41 price target. This event is significant as new analyst coverage, esp…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.